Extended Data Fig. 4: Neutralization studies of B.1.526-S477N.
From: Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York
a, Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing S477N alone or all five signature B.1.526-S477N mutations (L5F, T95I, D253G, A701V, and S477N), termed NYΔ5(S477N). Antibodies with emergency use authorization are shown in bold solid lines. Data are represented as mean ± s.e.m. of technical triplicates and represent one of two independent experiments. b, Neutralizing activities of convalescent plasma (n = 20) against NYΔ5(S477N) as well as against the authentic B.1.526 virus with S477N, and neutralizing activities of vaccinee sera (n = 22) against the NYΔ5(S477N) pseudovirus, compared to wild-type counterparts. Statistical comparisons were made using the Wilcoxon matched-pairs signed rank test; two-tailed P-values are reported.
